IDH1 and astrocytoma (excluding glioblastoma): A more recent study reported that PIK3R1 is uniquely overexpressed in IDH1-mutant grade 4 astrocytoma, indicating that combined targeting of the PI3K/AKT/mTOR pathway and the immune system may be necessary for effective treatment in this subtype [29].